lymphoma
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Galapagos to Begin US Trial for CAR T-Cell Therapy in Non-Hodgkin Lymphoma
The firm was cleared to begin the Phase I/II ATALANTA-1 trial studying GLPG5101, which is currently ongoing in Europe.
Gilead Optimistic About 11 Percent Q2 Growth in Cell Therapy Sales but Readying for Competition
Premium
The firm is working with providers to expand the use of Yescarta and Tecartus as competition from other CAR T-cell therapies and bispecifics heats up.
City of Hope, Institute for Follicular Lymphoma Innovation Partner on $2M Research Program
The three-year effort will use DNA profiling, proteomics, and machine learning techniques to explore potential triggers of spontaneous remission.
Clinical trial readouts later this year will provide the first indication of its RADR platform's potential to rescue drugs in biomarker-defined indications.
Mar 5, 2024